Dr. Ken Yu Lin, MD, PhD

Dr. Lin practices at Montefiore Einstein Hospital-Moses Campus in Bronx, New York, part of Montefiore Einstein.

Dr. Lin's NPI, 1063683936, was assigned on March 18, 2008. Dr. Lin graduated from Northwestern University Feinberg Medical School in 2007. Dr. Lin holds New York license 293320.

Dr. Lin's primary practice is Montefiore Einstein Hospital-Moses Campus, at 111 East 210th Street, Bronx, NY 10467 in Bronx County. The practice phone is (718) 920-4321.

Dr. Lin's primary practice is Montefiore Einstein Hospital-Moses Campus in Bronx, New York, part of Montefiore Einstein. Dr. Lin is also affiliated with Garnet Health Medical Center. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Dr. Lin to 1 more school health center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Lin is licensed in New York.

CMS data shows 315 Medicare services from Dr. Lin across 4 procedure codes in 2024, for 134 Medicare patients. Medicare paid $38,687 for them.

CMS counts 134 Medicare patients who saw Dr. Lin in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 26% are also on Medicaid. Their average risk score is 1.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 65, with 95% women.

In 2024, Dr. Lin wrote 191 Medicare Part D claims for 60 patients. 94% of them were for generic drugs. CMS names the drug for 103 of them, across 5 drugs with 11 or more claims each, at $2,994 in total drug cost. In 2023, CMS named 99 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. CMS lists Dr. Lin as offering telehealth. CMS counts 17 procedures of removal of the uterus by Dr. Lin, more than 90% of the clinicians it reports for that procedure.

Dmand AI links 23 papers to Dr. Lin, published from 2011 to 2025. 2021 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Ovarian Neoplasms and ADP-Ribosylation. Dr. Lin has published most often in Ann Oncol. Dr. Lin's most frequent co-authors are Jayanthi Sivasothy Lea, MD, Masoud Azodi, MD and Sara S. Isani, MD.

Dmand AI links Dr. Lin to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 36 general payments to Dr. Lin from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 82% of the total. Genentech, Inc. paid the most, $811.

Dr. Lin graduated from Northwestern University Feinberg Medical School in 2007.